Want To Promote Off-Label? Pick Your Battlefield

US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.

US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.

Amarin's win on Aug. 7 in convincing a federal judge in New York to permit the firm to share "truthful...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

More from Therapy Areas

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By 

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.